213 related articles for article (PubMed ID: 36925182)
1. A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies.
Seib CD; Beck TC; Kebebew E
Surg Oncol Clin N Am; 2023 Apr; 32(2):233-250. PubMed ID: 36925182
[TBL] [Abstract][Full Text] [Related]
2. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
3. Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.
Kihara M; Miyauchi A; Yoshioka K; Oda H; Nakayama A; Sasai H; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Ito Y; Kobayashi K; Miya A
Auris Nasus Larynx; 2016 Oct; 43(5):551-5. PubMed ID: 26837867
[TBL] [Abstract][Full Text] [Related]
4. Medullary Thyroid Cancer: Updates and Challenges.
Gild ML; Clifton-Bligh RJ; Wirth LJ; Robinson BG
Endocr Rev; 2023 Sep; 44(5):934-946. PubMed ID: 37204852
[TBL] [Abstract][Full Text] [Related]
5. Current understanding and management of medullary thyroid cancer.
Roy M; Chen H; Sippel RS
Oncologist; 2013; 18(10):1093-100. PubMed ID: 24037980
[TBL] [Abstract][Full Text] [Related]
6. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
Barletta JA; Nosé V; Sadow PM
Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
8. MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
Saltiki K; Simeakis G; Karapanou O; Alevizaki M
Eur J Endocrinol; 2022 Sep; 187(3):R53-R63. PubMed ID: 35895692
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
[TBL] [Abstract][Full Text] [Related]
10. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
[TBL] [Abstract][Full Text] [Related]
11. RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM; Cavaco BM; Leite V
Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
[TBL] [Abstract][Full Text] [Related]
12. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
[TBL] [Abstract][Full Text] [Related]
13. Genetics of medullary thyroid cancer: An overview.
Accardo G; Conzo G; Esposito D; Gambardella C; Mazzella M; Castaldo F; Di Donna C; Polistena A; Avenia N; Colantuoni V; Giugliano D; Pasquali D
Int J Surg; 2017 May; 41 Suppl 1():S2-S6. PubMed ID: 28506408
[TBL] [Abstract][Full Text] [Related]
14. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
[TBL] [Abstract][Full Text] [Related]
15. State of the art and future directions in the systemic treatment of medullary thyroid cancer.
Jager EC; Broekman KE; Kruijff S; Links TP
Curr Opin Oncol; 2022 Jan; 34(1):1-8. PubMed ID: 34669647
[TBL] [Abstract][Full Text] [Related]
16. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
[No Abstract] [Full Text] [Related]
17. Current Guidelines for Management of Medullary Thyroid Carcinoma.
Kim M; Kim BH
Endocrinol Metab (Seoul); 2021 Jun; 36(3):514-524. PubMed ID: 34154310
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
Jozaghi Y; Zafereo M; Williams MD; Gule-Monroe MK; Wang J; Grubbs EG; Vaporciyan A; Hu MI; Busaidy N; Dadu R; Waguespack SG; Subbiah V; Cabanillas M
Head Neck; 2021 Jan; 43(1):E7-E12. PubMed ID: 33169506
[TBL] [Abstract][Full Text] [Related]
19. Medical management of metastatic medullary thyroid cancer.
Maxwell JE; Sherman SK; O'Dorisio TM; Howe JR
Cancer; 2014 Nov; 120(21):3287-301. PubMed ID: 24942936
[TBL] [Abstract][Full Text] [Related]
20. Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma.
Miyauchi A; Matsuzuka F; Hirai K; Yokozawa T; Kobayashi K; Kuma S; Kuma K; Futami H; Yamaguchi K
World J Surg; 2000 Nov; 24(11):1367-72. PubMed ID: 11038208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
